The world is facing an unprecedented epidemic of diabetes. The International Diabetes Federation (IDF) estimates that there are 415 million adults living with diabetes worldwide. No country is immune from this epidemic: 70% of people with diabetes live in low- and middle-income countries.

Type 2 diabetes accounts for over 90% of all cases. The increase in type 2 diabetes is associated with modern-day lifestyles, characterised by unhealthy eating (foods high in sugar, salt and fat), physical inactivity and increasing obesity.

Diabetes causes high levels of glucose (a form of sugar) in the bloodstream. Over time, this damages blood vessels, with devastating effects in many different parts of the body, leading to heart attacks, stroke, foot amputations, kidney failure and blindness. It is these complications of diabetes that lead to premature death in so many. IDF estimates that, in 2015, five million people died from causes associated with diabetes. That is more than all the deaths from malaria, tuberculosis and HIV combined. The complications of diabetes also account for the staggering cost of treating diabetes, estimated at over US $670 billion dollars a year.

Diabetic retinopathy (DR) is caused by damage to retinal blood vessels. It is estimated that one third of people with diabetes have DR, and that up to a third of them have impaired vision. Although advanced DR can lead to blindness, the early stages are entirely asymptomatic. It is therefore essential that everyone with diabetes has their eyes examined for DR, ideally every year.

Nearly half of all people with diabetes don’t know they have the condition, so the damage to their eyes progresses to an advanced stage before there is an opportunity to prevent vision loss. This is tragic, as the risk of developing DR and vision loss can be reduced by keeping blood glucose, cholesterol and blood pressure as near normal levels as possible.

We need to build health systems that will help people to achieve good control of their diabetes through lifestyle changes and medication where required, and that will provide regular retinal screening to detect DR in its early stages, as well as laser or anti-VEGF treatment to prevent blindness. As most cases of type 2 diabetes can be prevented, there is also an urgent need to promote policies that support healthy lifestyles.

Unfortunately, we are far from achieving this ideal. Too many people already have advanced retinopathy at the time they are diagnosed with diabetes. Too many people with diabetes are not aware of the risk of blindness, and too many of those who see a doctor for their diabetes do not have their eyes examined.

Understanding the challenges: the DR Barometer project
The DR Barometer was a global project undertaken by IDF, the International Association for the Prevention of Blindness (IAPB), the International Federation on Ageing (IFA) and the New York Academy of Medicine. It collated the experiences of 3,590 people with diabetes and 1,451 health professionals from 41 countries across the globe. The preliminary findings were released at the EURETINA meeting in Nice in September 2015 and provided revealing insights.
One in five people with diabetes were not aware that diabetes could affect their vision. Of those who were aware, many reported that they did not know why, nor what they could do to prevent it. This highlighted the need for better education of people with diabetes about the risks of DR, and the importance of maintaining good blood glucose control.

One in four people with diabetes had not had their eyes examined in the previous two years. Two significant barriers were identified: the long wait times for an appointment and the high cost of the examination. This emphasises the need for accessible and affordable screening to be available to everyone with diabetes.

Over half of all health professionals did not have access to educational materials for patients. A similar proportion had no written protocol for the detection and management of DR. Nearly one in four eye specialists reported that they had received no training in the management of DR and 40% reported that there was poor integration of diabetes and eye care services. Until these fundamental deficiencies are addressed, progress in preventing vision loss in diabetes will be very slow.

What is being done to improve the situation?
Several organisations and initiatives are working hard to address diabetes and DR.
One of the key aims of IDF is the prevention of type 2 diabetes. It is active at the global and national levels, advocating that governments introduce policies to increase access to fresh, healthy foods and clean drinking water, and reduce consumption of unhealthy foods and sugar-sweetened beverages, which increase the risk of type 2 diabetes. In 2015, the World Health Organization (WHO) issued new recommendations to limit sugar consumption to no more than 5% of a person’s daily energy intake. In response, IDF published its Framework for Action on Sugar that detailed twelve actions to reduce consumption of sugar in the general population.
IDF also aims to improve the care of people with diabetes. In 2013, IDF and The Fred Hollows Foundation formed a partnership with the aim of improving the eye health of people with diabetes. The first outcome of this collaboration is Diabetes Eye Health: A Guide for Health Professionals. The guide includes practical information for primary health professionals to support them in discussing...
diabetes management for good eye health and detecting DR in people with diabetes. The guide will be published in the six UN languages (English, French, Spanish, Arabic, Chinese and Russian) and is available for download free of charge via the IDF website. It is hoped that this guide will help fill the gaps identified in the Barometer study and provide a framework to guide individual health professionals and local health systems in structuring screening and treatment services for DR. Further details of the Guide are presented in the panel below.

While some aspects of training in DR require hands-on instruction, much can be learnt online, by e-learning, and IDF is planning to develop interactive modules to make available the latest information on screening and treatment for DR. This will help health professionals to provide accurate information to people with diabetes from the moment they are diagnosed. IDF has recently launched the first of a two-part introductory module for non-specialist health professionals, aimed at equipping everyone involved in the care of people with diabetes with the knowledge they need to provide basic lifestyle advice (see Useful Resources below).

The Queen Elizabeth Diamond Jubilee Trust (QEDJT), through the Commonwealth Eye Health Consortium, has enabled the formation of the Diabetic Retinopathy Network (DR-NET) in 10 Commonwealth countries, whereby existing VISION 2020 LINKS between UK and overseas eye departments share learning on DR screening and treatment. In addition, DR-NET facilitates improved coverage of fundus cameras and screening databases and also works with Ministries of Health to implement national frameworks for diabetic retinopathy.

Further initiatives are planned in 2016 to promote better screening for, and treatment of, DR. There are excellent examples, such as the UK Retinal Screening programme, which demonstrate that effective population-based screening can be achieved. The challenge is to see this replicated elsewhere, in different national health systems and with different levels of resources. In order to build the evidence base for a structured approach to managing DR in low-resource settings, The Fred Hollows Foundation have partnered with the QEDJT and others to implement trials of models of care that integrate eye health into diabetes care in Pakistan, Bangladesh and the Pacific Islands.

What can eye health professionals do to improve the situation?

Unless we act now to develop prevention, screening and treatment services for DR, we face the prospect of nearly 40 million people experiencing vision loss from diabetes, all of whom will require multiple review and treatment visits. This will be a significant burden on top of ophthalmologists’ existing work load – even more so in low- and middle-income countries where there are very few of these specialists.

DR is preventable and blindness from DR is avoidable, but only if there is close collaboration between diabetes and eye health professionals at local, national and global level. In order to promote this, IDF and The Fred Hollows Foundation are exploring the creation of a global ‘DR Alliance’ to raise awareness of DR and to take the lead in recommending solutions to help address it.

In the meantime, we encourage all eye health professionals to improve the situation in their area in the following ways:

• Set an example by adopting a healthy lifestyle.
• Provide basic lifestyle advice to all patients, whether or not they have diabetes. This will help to prevent new cases of type 2 diabetes and help prevent DR in those with diabetes.
• Ensure patients with diabetes are being appropriately monitored by a primary care or specialist diabetes physician. This is especially important for those with DR.
• Build links with local diabetes professionals to develop reliable care pathways for patients with DR and set up a screening (fundus) camera in the diabetes clinic, so it is easily accessed by the target population.

Useful resources


### Diabetes Eye Health: A guide for health professionals

The rising number of people developing diabetes worldwide means there will be an increasing number of people with diabetic eye disease. Early detection and treatment of diabetic retinopathy (DR) is needed to reduce the burden of vision loss on individuals, their caregivers and society.

Specialised eye health practitioners have an important role to play in addressing DR; however, as they are a relatively limited resource, their focus should be on treatment. The support of primary health practitioners – the general practitioners, family doctors, nurses, endocrinologists and others who manage the primary care of people with diabetes – is therefore vital for the early diagnosis and timely management of diabetic eye diseases.

Many people with diabetes – as well as many health professionals – are unaware of the critical need to undergo regular eye examinations. Primary health professionals, through their routine care of people with diabetes, are the ones most likely to have the opportunity to screen patients and to educate and support them to manage their diabetic eye disease. They can also facilitate the timely referral of patients to eye specialist services for treatment to reduce sight loss.

It is with this in mind that the International Diabetes Federation (IDF) and The Fred Hollows Foundation launched ‘Diabetes Eye Health: A Guide for Health Professionals’ last year. The purpose of the guide is to educate and inform primary health care professionals about diabetic eye diseases and to show them, in very practical ways, what they can do to address the rising prevalence of diabetic-related eye disease, particularly diabetic retinopathy.

The three key actions by health professionals to manage eye health in people with diabetes are:

1. Helping people with diabetes to optimise their control of blood glucose, blood pressure and blood lipids in order to slow down the progression of diabetic retinopathy.
2. Ensuring that people with diabetes have regular eye examinations and timely treatment when required.
3. Educating and supporting people with diabetes to manage their own eye health and their diabetes.

We would like to encourage readers concerned about DR to make contact with the relevant primary health care workers in your area. Share with them the key messages in this article, offer information about Diabetes Eye Health: A Guide for health professionals and inform them about any diabetic eye disease services available in your area.

Management of diabetic eye disease: an overview

Systemic risk factors

In order to reduce the risk of diabetic eye disease (both retinopathy and maculopathy) progressing and causing visual loss, it is important for all people with diabetes to maintain good overall health and good control over their diabetes. This is especially important for patients who already have diabetic retinopathy (DR) which is already affecting their vision, or is likely to damage it soon.

The two most important risk factors are high blood glucose (sugar) and high blood pressure.

High cholesterol and lipids also seem to be related to DR getting worse. Treatment of high cholesterol and lipids with statin medications, if available, reduces the risk of DR progressing. Maintenance of a healthy lifestyle overall will be beneficial for DR. People with diabetes should follow a healthy diet and avoid sugar and refined carbohydrates as much as possible.

Eye health professionals have a role in identifying patients at risk of sight loss from DR, and reinforcing messages about diabetes control and healthy living. Screening for DR and laser treatment for DR are both good opportunities for eye health professionals to get these messages across to patients.

Table 1. Indications, response indicators and side effects of laser treatment for maculopathy and retinopathy

<table>
<thead>
<tr>
<th>Indications</th>
<th>Laser for diabetic retinopathy (DR): peripheral retinal photocoagulation (PRP)</th>
<th>Laser for maculopathy (focal or grid laser)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe pre-proliferative DR</td>
<td>Regression of new vessels</td>
<td>Clinical significant macular oedema (CSMO)</td>
</tr>
<tr>
<td>4-2-1 rule (see page 65)</td>
<td>Prevention of new vessel formation</td>
<td>Diabetic macular oedema (DMO) affecting the central fovea</td>
</tr>
<tr>
<td>Proliferative DR</td>
<td></td>
<td>Exudates threatening/affecting vision</td>
</tr>
<tr>
<td>Proliferative DR with high-risk characteristics (new vessels or vitreous haemorrhages)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Insufficient response?</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reapply PRP, making burns more dense and extensive</td>
<td>Reduction in DMO</td>
<td>Once grid is complete over oedematous area (or macula in diffuse DMO) no benefit from further grid laser. Individual microaneurysms can be targeted.</td>
</tr>
<tr>
<td>Keep repeating</td>
<td>Prevention of (further) deterioration of vision</td>
<td>Foveal burn</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Side effects and complications</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction in night vision and peripheral vision</td>
<td></td>
<td>Foveal burn</td>
</tr>
<tr>
<td>Initiating/worsening DMO</td>
<td></td>
<td>Paracentral scotomas for deliberately close laser shots</td>
</tr>
<tr>
<td>Foveal burn (rare)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Preventing sight loss from proliferative diabetic retinopathy

The keys to preventing sight loss from proliferative DR are as follows.

1. Identify the right patients to treat with peripheral retinal photocoagulation (PRP). PRP is destruction of the peripheral retina using laser, with a minimum of 2,000 effective burns.

2. In those with established new vessels, treat them with enough PRP and, if the response to PRP is insufficient, keep going with more and more.

When to do laser

In patients with obvious new vessels at the disc (NVD) or elsewhere in the fundus (NVE), or if there is some vitreous haemorrhage associated with new vessels, it is a straightforward decision: treat them with PRP. (These are called ‘high-risk characteristics’ because there is a high risk of visual loss in the ensuing years.)

There are also benefits to treating patients with less advanced DR. The Early Treatment in Diabetic Retinopathy Study (ETDRS) showed that PRP treatment can prevent these patients from progressing to the high-risk state. In a resource-poor setting where follow-up of patients may be haphazard, or patients are unable to attend for regular appointments, treating patients with less severe disease will prevent them getting worse. The threshold which ETDRS has established for laser has become known as the 4-2-1 rule (see panel below) and equates to severe pre-proliferative DR. Patients with this level of DR and above should be treated.

Continues overleaf ➤

The 4-2-1 rule

The 4-2-1 rule is:

- 4 quadrants of the fundus with dense retinal haemorrhages and microaneurysms; or
- 2 quadrants with venous beading; or
- 1 quadrant with intra-retinal microvascular abnormalities (IRMA).

These are all signs of retinal ischaemia, which is the stimulus for eventual new vessels – leading to tractional retinal detachment, vitreous haemorrhage and visual loss.

When are haemorrhages and micro-aneurysms dense?

The ETDRS study referred to standard photographs (Figure 1), if these are not available a rule of thumb is 5 or more haemorrhages and micro-aneurysms in a 1 mm wide slit, wherever in the quadrant you place the slit with a 90D lens.

Venous beading is clear dilation of retinal venules with accompanying constriction so it looks like a string of sausages.

IRMAs are abnormal branching, or network of vessels within the retina. ETDRS used standard photographs to define the size of IRMA that was significant. In a low- or middle-income country setting, with unreliable follow up, any definite IRMA warrants laser treatment.

Cotton wool spots are also a sign of retinal ischaemia and tend to occur in the border between well-perfused and poorly perfused retina. Although not part of the threshold, cotton wool spots are important in gaining an assessment of retinal ischaemia particularly in the absence of fluorescein angiography. They can push the clinician towards laser treatment.

Remember, these signs tend to occur together, so where there are cotton wool spots or dense haemorrhages or micro-aneurysms, look closely for IRMA or venous beading.

Glossary

Clinically significant macular oedema (CSMO)

CSMO is when leakage from small retinal blood vessels causes macular oedema (retinal swelling) and exudates (fat deposits from the blood) which are sufficiently close to the fovea (central macula) to affect or threaten the vision.

Diabetic maculopathy

Diabetic maculopathy is part of diabetic retinopathy. Maculopathy is damage to the macula, the part of the eye responsible for central vision.

Diabetic macular oedema (DMO)

Diabetic macular oedema occurs when blood vessels near to the macula leak fluid or protein onto the macula.

Diabetic retinopathy (DR)

Diabetic retinopathy occurs when changes in blood glucose levels cause changes in retinal blood vessels. In some cases the vessels leak fluid into the macula part of the retina which swells up (DMO). In other cases, abnormal blood vessels will grow on the surface of the retina.

Peripheral retinal photocoagulation (PRP)

Cauterisation of the peripheral retina using laser, with a minimum of 2,000 effective burns.

Proliferative diabetic retinopathy

This is the advanced stage of diabetic retinopathy. New blood vessels grow along the inside surface of the retina and into the vitreous gel, the fluid that fills the eye. These vessels are fragile and more likely to leak and bleed. Scar tissue is formed and can contract and cause retinal detachment (the pulling away of the retina from underlying tissue) – which results in blindness.

The Early Treatment in Diabetic Retinopathy Study (ETDRS)

The Early Treatment in Diabetic Retinopathy study (ETDRS) has produced over 20 publications. They are listed at https://clinicaltrials.gov/ct2/show/study/NCT00000151

ETDRS and the preceding Diabetic Retinopathy Study are summarised in Chapters 1 and 2 of Clinical Trials in Ophthalmology, Eds PJ Kertes and MD Conway. Lippincott Williams and Wilkins 1998.
Tips for successful laser

It is important that, before you start, the patient knows what to expect and what the aims of treatment and potential side effects are. In particular, you should stress that the laser treatment is to prevent visual loss in the future and is not intended to improve vision. At the start of the treatment, titrate the strength of the laser burn and adjust the laser power to achieve a visible burn which is not too harsh or bright white.

Remember: doubling the duration or power doubles the fluence (laser energy delivered per square millimetre), whereas halving the diameter increases the fluence by a factor of 4.

Modern spot sizes are smaller than in the ETDRS era, 200 microns being the standard. The duration of each laser burn is also shorter, and I recommend 0.02 s (20 ms). This reduces the laser injury and you do not have to worry about lasering over retinal vessels with this short duration. I start with 200 mW laser power if there is a clear lens. In patients with lens opacity, more power is required. Increase the power in 50 mW steps until a burn is visible. If it is too harsh (it will appear white, with a sharply defined edge), turn the power down in 25 mW steps (Figure 2). The central retina is thicker than the peripheral retina, so if you start centrally, you will have to reduce the power as you treat more peripheral retina.

The temporal quadrant is often under-treated and a zone of significant ischaemia, as it is a watershed between the vascular arcades. The laser should be brought up to the temporal edge of the macula, approximately 2 disc diameters from the foveal centre. It helps to define this border temporarily with laser burns and work progressively peripherally away from it to avoid inadvertent macular coverage, or worse, a foveal burn. The clinician should know where the macula is at all times.

NOTE: If during the treatment you have lost visible burns with the fluence unchanged, it is usually either a focusing issue or loss of coupling gel in the contact lens. Pause, detach the lens, refill with gel and continue.

To treat pre-proliferative disease, 2,000 to 3,000 effective burns are usually sufficient, particularly if you are relatively certain that the patient will return for an examination and further treatment if needed. With proliferative DR, more burns may be required.

Call patients back for a follow-up visit to see if the new vessels regress over the following 3–6 months. If they are not regressing, more treatment is needed. In this scenario, you should treat between the original burns, up to 500 microns from the nasal disc edge and within the arcades, with two or three burn rows and as far into the peripheral retina as you can reach with your lens. Around 5,000 burns may be required.

White fibroglial tissue will not disappear, but you are aiming to get the vascular component to regress. However, the longer the new vessels have been present (often associated with glial tissue), the harder it will be to get them to regress completely. It is okay to accept incomplete regression if the situation is stable, and you have done as many burns as you think is reasonable.

If there is vitreous haemorrhage it is very important to apply as much laser treatment as possible, as quickly as possible, whilst there is a view. There may be a small vitreous haemorrhage with scope for laser, before a larger one obscuring your view prevents any treatment. Where there is a small vitreous haemorrhage, laser is therefore urgent – because any subsequent and more severe haemorrhage is likely to have a much better outcome if the DR had been treated before the haemorrhage occurs.

Complications and side effects of peripheral retinal laser (PRP)

PRP inevitably sacrifices some peripheral retina, but in most cases this does not have any effect on vision. In about 10% of cases, patients notice a reduction in visual field or night vision.

The effect on night vision may be more noticeable in low-income countries, where night vision is essential. The more PRP is required, the more likely this is to be an issue and it may affect the person’s ability to drive. This is a trade-off with preserving any vision at all.

A foveal burn, affecting central vision, is possible but should not happen if the operator makes sure where the macula is at all times, and only switches the equipment from ‘standby’ to ‘treat’ when she or he is ready to start lasering.

Macular oedema can be induced by an aggressive and extensive PRP session. This can damage the patient’s confidence by making the vision worse afterwards. If possible PRP should be offered in two treatment sessions of about 1,500 burns each to avoid this. If necessary, macular laser should be applied before PRP or at least at the same time as the first session if the PRP is urgent.

Role of antiVEGF in PDR

Intra-vitreal anti-VEGF injections such as bevacizumab (Avastin) only buy time until more definitive treatment. One special situation in which they might be of benefit is where severe ischaemia has led to rubeotic glaucoma. An injection of bevacizumab can induce regression of new vessels, reduce IOP, improve pupil dilation and allow laser application. Bevacizumab can be used just prior to vitrectomy to reduce bleeding during surgery and make it technically easier. However, new vessels may recur aggressively if definitive laser treatment is not commenced within a month.

Surgery for proliferative DR

Vitrectomy surgery has limited availability, particularly in sub-Saharan Africa. Early treatment with laser should reduce the need for vitrectomy, however patients will inevitably present late particularly with vitreous haemorrhage resulting in sudden visual loss. This is the commonest indication for vitrectomy in DR. Where there is any view of the fundus, PRP is indicated. When there is not there are two scenarios: the patient who has had previous PRP and the patient who has not. If a patient has previously had a complete PRP then you
Laser treatment is less successful at reducing the risk of diabetic macular oedema (DMO) causing visual loss compared to peripheral retinal photocoagulation for proliferative diabetic retinopathy. Intravitreal treatments are effective but often unavailable due to cost and access to treatment.

**When to do macular laser**
The threshold for macular laser is usually clinically significant macular oedema (CSMO) as defined in the Early Treatment of Diabetic Retinopathy Study (ETDRS). CSMO is any retinal thickening (oedema) and/or exudates within 500 microns (¼ disc diameter) of the centre of the fovea; or oedema greater than 1 disc area within 1 disc diameter of the foveal centre – including oedema which involves the fovea already. Macular laser is more effective if the DMO is localised (focal maculopathy), than if it is generalised across the central macula (diffuse maculopathy). Optical Coherence Tomography (OCT) scans enable visualisation of macular oedema in great detail, but are not required to determine whether a patient meets the thresholds for macular laser, because these were determined prior to the advent of OCT.

Exudates, if they involve the fovea, can sometimes threaten or affect vision without macular oedema. Exudates without oedema within 500 microns of the foveal centre, particularly long or streak exudates pointing towards the centre, are an indication for laser.

### Tips for successful macular laser

Macular laser is much more gentle and measured than peripheral retinal photocoagulation (PRP). Macular laser can be directed at microaneurysms, or applied in a grid pattern over the oedematous zone. Macular laser is usually given as a combination of both, which is known as a Modified Macular Grid: the microaneurysms are targeted first, and untreated areas of oedema are then treated in a grid pattern (see Figure 3).

Although it is important to make sure that the laser beam is focused in PRP, this is critical in macular laser. Retinal lasers are not in a parallel beam but converge to a focus. Whilst setting up the laser, make sure that the laser focus and the optical focus of the slit lamp are in the same plane. Lasers are usually supplied with a test rod, but the focus adjustment can be done on the fundus with the laser in standby. Focus the aiming beam, and then adjust each eyepiece until the view is also in focus.

**For macular laser:**
- The default laser spot size is 100 microns; however, smaller sizes can be used if small microaneurysms are being targeted and the patient is very still.
- Short durations, such as 0.02 s, result in less retinal damage but may need to be increased for microaneurysm treatment.
- The power should be low to start with (100 mW) and increased in steps of 50 mW as necessary (the same as for PRP). However, the desired burn should be just visible (less visible than for PRP).
- Titrate the laser power away from the fovea, on the edge of the macular oedema. This is because uptake is less good within zones of oedema. It may be necessary to increase the power in zones of oedema, but limit this to an increase of 100mW.
- For a first macular laser treatment, the laser burns should be 750 microns (half a disc diameter) from the centre of the fovea. If the fovea is hard to discern then the inner ring should be wider, outside the zone including the fovea.
- Most operators like to start with the inner ring after titrating the laser power, and then move outwards to complete 4–6 rings. This should create an adequate grid to treat a diffuse maculopathy.
- If further treatment is required, and the patient can keep still, a further ring, 500 microns (¼ disc diameter) from the centre, can be added. However, once the grid is complete there is nothing to be gained by further grid laser. This is unlike PRP, where fill-in laser can be repeated many times if necessary.
- When targeting microaneurysms, the ideal result from laser is a colour change. However, it is difficult to land a direct hit with one shot, and not more than 5 attempts should be made on an individual microaneurysm. As microaneurysms occur in the thickened retina, it may be necessary to focus slightly anteriorly to treat them accurately.
- The spaces between burns for the grid laser should be approximately the width of 1 spot.

Macular laser takes 8 weeks to a year to have its full effect so do not rush to judge it. The main aim is to prevent deterioration of vision, and the recent trials with a laser cohort show that stable vision is about what is achieved on average. However, for focal maculopathy with good vision, maintenance of that good vision with laser is well worthwhile.

---

**Complications of macular laser**
The complication to be avoided in macular laser is foveal burn. This can occur if:

1. Microaneurysms closer than 500 microns (¼ disc diameter) from the foveal centre are targeted.
2. If care is not taken to avoid the whole central macula when the position of the fovea is unclear.
3. If the patient moves suddenly.

The worst scenario is immediate loss of central vision, but with short laser durations this can be...
Role of intravitreal treatment in maculopathy
Recent studies have shown that anti-VEGF treatment produces greater visual improvements than laser in patients with central diabetic macular oedema (DMO) whose vision is reduced to 6/12 or worse. These intravitreal injections reduce DMO rapidly and effectively. Laser treatment usually prevents loss of vision but does not often lead to visual improvement. Repeated injections of bevacizumab in eyes with visual acuity of less than 6/12 give an average improvement of two lines on the Snellen chart, and about a quarter of patients will improve by three lines. However, they have a number of problems – notably cost, the treatment burden of monthly injections, and the risk of infection/endophthalmitis. Even the relatively low cost of bevacizumab is prohibitive to many patients in low- and middle-income countries. Furthermore, a reliable pharmacy is required, one which can divide the intravenous dose into intravitreal doses in sterile conditions. Clusters of endophthalmitis cases in the US and UK have led to a suspicion of contaminated batches of anti-VEGF preparations. This is a definite concern in less well-regulated areas.

Evidence from clinical trials suggests that patients require 9–12 injections in the first year, so the treatment regimen is intense – requiring frequent revisits in order to maximise the benefits. After the first year, the overall treatment burden is less, but some patients have recurring DMO requiring ongoing retreatments.

Despite these problems, the greater effectiveness of intravitreal injections means that they may be valuable for some patients, particularly those who can afford the drug costs and live sufficiently near to the clinic to attend for repeated treatment.

An alternative intravitreal treatment is steroid, the least costly being triamcinolone. This is effective, but visual gains are reduced by induced cataract, and even after cataract surgery on average the vision does not catch up with that from anti-VEGF therapy. This may be due to exacerbated DMO or postoperative cystoid macular oedema. Intravitreal steroid is an option, especially in patients who are already pseudophakic. Post-injection intraocular pressure (IOP) rise can be a problem, so this needs to be monitored and treated accordingly.

Diabetic retinopathy is one of the many complications of diabetes. Because there are no symptoms initially, patients will not realise that they have the condition until it is at a proliferative stage or they develop macular oedema, when their vision becomes affected. Unfortunately, vision that has been lost may never be regained.

To prevent visual loss, early detection is needed at the pre-proliferative stage. This can only be achieved if the person with diabetes has regular (often annual) examination of the retina, starting from when they are first diagnosed. Screening of diabetes patients therefore has to be timely and in accordance with locally agreed guidelines for detection, referral and treatment. The challenge faced across many programmes is that people with diabetes:

- Do not always attend regular DR screening
- Present with late-stage retinopathy which results in a poor visual outcome

In national population-based screening programmes, the desirable target uptake is 80%, which is difficult to achieve. The UK National Screening Programme took five years from the start of the programme in 2006 to reach this target. Attendance for initial laser treatment is reportedly around 70%, but in some studies as few as 21–45% of those patients who started laser treatment had completed the course of laser when they were followed up 6 months later.

Why do patients not attend?

Reasons for non-attendance in various settings have been studied qualitatively and quantitatively and common themes arise.

Patient-related reasons

These can be remembered using the first 7 letters of the alphabet.

- Awareness about diabetes and eye complications is often limited. Patients may not be aware of local screening centres
- Belief that they do not require retinal examinations or treatment as their vision is good, or they have a mild form of diabetes, or are too old
- Cost: direct and indirect (e.g. travel)
- Distance from screening/treatment centres and discomfort from dilating drops
- Effort to attend yet another clinic.
- People with diabetes often have multiple hospital appointments
- Fear of laser treatment and fear of its impact on quality of life and jobs. A lack of family support
- Guilt surrounding failure to control blood glucose levels. People fear that an eye examination, or being told they need laser treatment, will confirm their guilt and make them feel even worse.

Provider-related reasons

- The existence of poor counselling and advisory services about ocular complications for people with diabetes
- An inefficient system for getting patients to come, and to then come back if needed (‘call and recall’ systems)
- Long waiting times for screening or treatment
- Complicated referral mechanisms or inaccessible locations where services are offered.

Assessing the situation

The different factors in patients’ experience – which either prevent or encourage their engagement – should determine what interventions might improve uptake of services. By assessing the situation and identifying key stages in the process (from screening to completion of treatment) we can target interventions at those most at risk of vision loss.

The non-attendance rate

This is the proportion or percentage of patients who do not attend their appointments, whether for their yearly eye examination or for laser treatment. We should aim to make this figure as low as possible.

At a clinic level, work out the non-attendance rate, say for 1 month, by dividing the number of patients who did not attend their appointment (for screening, the eye clinic or laser treatment) by the number of patients who have appointments in that time period. Multiply by 100 to obtain the percentage.

Coverage

Coverage is the percentage or proportion of the target population who undergo screening. In the case of diabetic eye disease, ‘screening’ means yearly eye examination and the percentage of eyes examined.
examinations for everyone diagnosed with diabetes. Coverage is an important measure of the quality of a programme, and we should aim to make this figure as high as possible.

To work out the coverage offered by your clinic or programme, divide the number of patients who attended screening on a yearly basis by the number of patients with diabetes in your catchment population; multiply by 100 to calculate the yearly coverage of screening as a percentage.

The pathway
Can you identify which part of the pathway, from screening to treatment, is most affected by non-attendance?

Is there a particular geographic location where assessments or treatment take place, where non-attendance is higher?

Who is not coming?
Among the diabetes patients, can you identify any particular subgroup who would benefit most from a targeted intervention? (For example, younger patients, those newly diagnosed, people with language barriers, or people with low social economic status or poor education.)

Addressing the challenges
The following practical suggestions are gathered from patient recommendations, models of good practice and successful interventions. Together, they improve the overall patient experience, improve ease of access to services, and encourage and engage the patient through education.

Empower health professionals
• Encourage all allied health professionals working with diabetes to personally recommend annual retinal checks to patients with diabetes. Train health workers to offer intensive patient education programmes to all newly diagnosed patients, covering specifically diabetes, potential blindness and the eye.
• Encourage health workers to support patients with diabetes (especially those with poor control) and work with them to find solutions to the challenges of having diabetes. It is vital not to blame the patient or make them feel guilty.

Strengthen patient communication
A diabetes ‘passport’ has been a useful tool to encourage patients to feel ownership of their disease and facilitate communication between health professionals and the patient. The patient brings the passport (a specially designed booklet or file) to every appointment and health professionals record current medications and results (blood sugar, blood pressure, cholesterol, kidney function, podiatry assessment and retinopathy grading) as well as when new assessments are due. The passport helps to start conversations with the patient about their diabetes.

Waiting times and dilation
• Seeing patients punctually and efficiently will reduce time off work and encourage them to return each year.
• Retinal photography without dilation drops is possible, but in older patients with cataract their photographs may be ungradable and patients will need to be called back, unless quality assessment is done by the photographer at screening.

Centralised services
• Some services have combined diabetic retinopathy screening with other check-ups such as blood pressure monitoring or annual flu immunisations.
• Centralised booking systems can reduce administration and costs but may offer less flexibility for those who present opportunistically, or for family members who want to attend together.

Improving compliance with laser treatment
• Educate patients about laser treatment, its intended effect, the need to complete the course (at least two visits are usually needed) and the need to allow time to evaluate its effectiveness. This should take place at the time of consenting to laser treatment.
• Written and visual information (retinal images) supporting the discussion should be available.
• The health professional applying the laser should ensure that the patient is made comfortable, with appropriate anaesthesia and minimum effective power settings.
• If unable to achieve comfortable laser treatment with topical anaesthesia, there should be the option to give a local anaesthetic block, or even general anaesthesia with indirect laser.
• Health professionals should understand the discomfort which may be caused by laser, and offer sympathy rather than irritation or denial, thereby establishing a good relationship and encouraging the patient to return.

Practical considerations
Giving attention to the following practical arrangements can support patients to attend their appointments more regularly.

Cost and accessibility
• Minimise the cost to the patient by reducing the time required and the distance travelled.
• Locate screening where there are good transport links.
• Ensure that patients can change the appointment to a more convenient time, especially if they are employed.
• Patients prefer their annual visits to be repeatable. Keep the location and routine the same, if possible, so they can become familiar with the process.

Show patients their retinal images and highlight any changes.

Offer personalised annual education
• Screeners or ophthalmologists can show patients their retinal images and highlight any changes (improvements or deteriorations) to encourage future attendance and good glycaemic control.
• Information should be available to the patient in their preferred language and in large print.

Identify and engage patients who frequently fail to attend
• A common policy in eye clinics is to discharge patients who do not attend on two occasions. However, in diabetic eye services, these patients should be identified and contacted personally to understand their reasons for poor attendance (e.g. timing, transport, or anxiety) and solutions must be found.
• Set up a reliable system. For example, use text messaging and send reminders for patients about their appointments.
• Large-scale programmes benefit from employing a diabetic retinopathy co-ordinator who is responsible for monitoring the quality of the programme and ensuring that people keep coming back for their appointments. For more information on this, see www.gov.uk/topic/population-screening-programmes/diabetic-eye

Conclusion
Improving patient engagement with preventative services requires persistent effort and innovation from service providers. Whilst laser treatment is still the best way of preventing significant visual loss, we are in a new era of treatment with anti-VEGF injections which are given monthly. Preventative services requires persistent effort and innovation from service providers. Whilst laser treatment is still the best way of preventing significant visual loss, we are in a new era of treatment with anti-VEGF injections which are given monthly. Improving patient engagement, education, and compliance will be even more crucial if these new treatments are to be effective.

Further reading
Lee, H. Service innovation to help people live well with diabetes and reduce sight loss. RNB. 2015.
Diabetic retinopathy (DR): management and referral

This diabetic retinopathy (DR) grading system is based on the International Council of Ophthalmology’s diabetic retinopathy and diabetic macular oedema disease severity scales. At whatever level you work, you must encourage everyone with diabetes to manage their blood sugar and blood pressure. Refer them to available services for help if they are not sure how to do this, or if their control is poor.

Diabetic retinopathy stage | Clinical signs | What to do (screening/primary eye care) | What to do (retinal clinic) | What you could say to your patients
--- | --- | --- | --- | ---
No diabetic retinopathy | No abnormalities | Encourage patient to come again in 12 months | Review in 12 months | Diabetes can affect the inside of your eyes at any time. It is important that you come back in twelve months so we can examine you again. This will help to prevent you losing vision or going blind.
Mild non-proliferative diabetic retinopathy | Microaneurysms only | Encourage patient to come again in 12 months | Review in 12 months | Your diabetes is affecting your eyes. At the moment your vision is good, but we must check your eyes in 12 months’ time to see if these changes are getting worse. If the damage becomes severe, we will need to treat your eyes to stop the diabetes affecting your sight.
Moderate non-proliferative diabetic retinopathy | More than just microaneurysms but less than severe non-proliferative retinopathy | Encourage patient to come again in 6-12 months | Review in 6–12 months | Your diabetes is damaging your eyes. At the moment your vision is good, but we must check your eyes in six months’ time as it is likely that these changes will get worse. If the damage becomes severe, we will need to treat your eyes to stop the diabetes affecting your sight. Unless you are treated promptly, you risk losing vision or going blind.
Severe non-proliferative diabetic retinopathy | More than 20 haemorrhages in each quadrant; venous beading in two quadrants; or intraretinal microvascular abnormalities (IRMA) | Refer to retinal clinic. All patients with severe non-proliferative DR should be in the care of an ophthalmologist. The patient should be re-examined every six months | Perform peripheral retinal photocoagulation if follow-up is unreliable; otherwise review in 6 months | Your diabetes has damaged your eyes quite severely, although your vision is still good. You are likely to need treatment soon to ensure that you don’t lose vision or go blind. We must check your eyes in six months’ time. However, if you think you may not be able to come then, we may treat your eyes now, so we can be sure you don’t lose vision later.
**Diabetic retinopathy**

Clinical signs

<table>
<thead>
<tr>
<th>Stage</th>
<th>Description</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>No diabetic</td>
<td>No abnormalities</td>
<td>Continue as usual.</td>
</tr>
<tr>
<td>Mild non-proliferative</td>
<td>Microaneurysms only</td>
<td>Review in 12 months.</td>
</tr>
<tr>
<td>Moderate non-proliferative</td>
<td>More than just microaneurysms but less than 20 haemorrhages</td>
<td>Encourage patient to come again in 6–12 months.</td>
</tr>
<tr>
<td>Severe non-proliferative</td>
<td>More than 20 haemorrhages</td>
<td>Refer to retinal clinic.</td>
</tr>
</tbody>
</table>

**Macular oedema**

<table>
<thead>
<tr>
<th>Macular oedema</th>
<th>Description</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absent</td>
<td>No exudates or retinal thickening in posterior pole</td>
<td>Review in 12 months.</td>
</tr>
<tr>
<td>Mild</td>
<td>Exudates or retinal thickening at posterior pole, &gt;1dd from fovea</td>
<td>Review in 6 months.</td>
</tr>
<tr>
<td>Moderate</td>
<td>Exudates or retinal thickening at posterior pole, 1dd or less from fovea, but not affecting fovea</td>
<td>Refer to retinal clinic. Encourage patient to manage their blood sugar and blood pressure, and refer them to available services for help if they are not sure how to do this.</td>
</tr>
<tr>
<td>Severe</td>
<td>Exudates or retinal thickening affecting centre of fovea</td>
<td>Refer to retinal clinic. Laser treatment if clinically significant macular oedema (CSMO).</td>
</tr>
</tbody>
</table>

If you cannot see the retina due to cataract or vitreous haemorrhage, refer to an ophthalmologist for cataract surgery or a retinal surgeon for vitrectomy.
Although traditionally the features of DR have been identified through direct ophthalmoscopy or slit lamp biomicroscopy, digital photography is more sensitive than direct ophthalmoscopy and is comparable to slit lamp examination by a trained observer.1

A digital fundus camera has the following advantages:

• Fast and convenient imaging of the retina by a photographer
• Storage, archiving, and transmission of the images
• Use of the images for quality assurance (that is, having them checked by another person) to ensure that no cases of retinopathy go undetected
• Ability to enhance images – magnification, red-free, enhanced contrast, etc.

When using the Scottish Grading Protocol2, just one retinal photograph is taken, which is centred on the fovea. The field must extend at least 2 disc diameters (DD) temporal to the fovea and 1DD nasal to the disc for adequate visualisation.

Features of retinopathy
The signs of diabetic retinopathy are covered on page 65 and on pages 70–71. For DR screening, certain signs are more important than others.

Blot haemorrhages should be distinguished from microaneurysms, not just by their darker appearance but also by their size – the larger diameter of a blot haemorrhage should be equal in size to, or larger than, the diameter of the widest vein exiting from the optic disc.

Chronic retinal oedema results in precipitation of yellow waxy deposits of lipid and protein known as exudates. When blot haemorrhages and exudates are visible within the macular area, they are considered markers for macular oedema.

Signs of retinal ischaemia include blot haemorrhages, venous beading and intra-retinal microvascular anomalies (IRMA).

Venous beading is a subtle change in the calibre (thickness) of the second and third order retinal veins which gives them an irregular contour resembling a string of beads. IRMA look like new vessels; however they occur within areas of capillary occlusion and do not form vascular loops. Unusual vessels with loops therefore, should be treated as NV.

Grading of DR
Most grading protocols are based on classification systems for DR which track the appearance and progression of disease (for example, the Early Treatment of Diabetic Retinopathy Study, or EDTRS, classification). Location (distance from fovea) is important when grading maculopathy. Visual acuity can be used as a marker for macular oedema, although it may be affected by other pathology such as cataracts or refractive error.

The Scottish Grading protocol grades the severity of retinopathy from R0 to R4 and of maculopathy as a separate grade from M0 to M2 (Table 1). R6 is a stand-alone grade for poor quality images which cannot be graded. If patients have technical failures at photography they must undergo further screening by slit lamp biomicroscopy.

‘For DR screening, certain signs are more important than others’

Figure 1. R3M2, The photograph shows multiple blot haemorrhages, corresponding to the R3 grade. In addition there are exudates within 1 disc diameter to the fovea, so the complete grade is R3M2

Figure 2. R3. There are blot haemorrhages and cotton wool spots. In addition there is a venous loop inferotemporal to the fovea. These features indicate severe ischaemia, corresponding to R3. There are no exudates visible

Sonia Zachariah
Associate Specialist: Diabetic Retinopathy Screening Service, Glasgow, Scotland.

William Wykes
Consultant Ophthalmologist and Clinical Director: Diabetic Retinopathy Screening Service, Glasgow, Scotland.

David Yorston
Consultant Ophthalmologist: Tennent Institute of Ophthalmology, Gartnavel Hospital, Glasgow, UK.

dbyorston@btinternet.com

Figure 1. R3M2, The photograph shows multiple blot haemorrhages, corresponding to the R3 grade. In addition there are exudates within 1 disc diameter to the fovea, so the complete grade is R3M2

Figure 2. R3. There are blot haemorrhages and cotton wool spots. In addition there is a venous loop inferotemporal to the fovea. These features indicate severe ischaemia, corresponding to R3. There are no exudates visible
Table 1. The different grades of diabetic retinopathy (DR) in the Scottish Grading Protocol: features and outcomes

<table>
<thead>
<tr>
<th>Grade</th>
<th>Features</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>R0</td>
<td>No disease</td>
<td>Rescreen in 12 months</td>
</tr>
<tr>
<td>R1</td>
<td><strong>Mild background DR</strong> Including microaneurysms, flame exudates, &gt;4 blot haemorrhages in one or both hemifields, and/or cotton wool spots</td>
<td>Rescreen in 12 months</td>
</tr>
<tr>
<td>R2</td>
<td><strong>Moderate background DR</strong> &gt;4 blot haemorrhages in one hemifield</td>
<td>Rescreen in 6 months</td>
</tr>
<tr>
<td>R3</td>
<td><strong>Severe non-proliferative or pre-proliferative DR:</strong> &gt;4 blot haemorrhages in both hemifields, intra-retinal microvascular anomalies (IRMA), venous beading</td>
<td>Refer</td>
</tr>
<tr>
<td>R4</td>
<td><strong>Proliferative retinopathy</strong> NVD, NVE, vitreous haemorrhage, retinal detachment</td>
<td>Refer</td>
</tr>
<tr>
<td>M0</td>
<td>No macular findings</td>
<td>12 month rescreening</td>
</tr>
<tr>
<td>M1</td>
<td>Hard exudates within 1–2 disc diameters of fovea</td>
<td>6 month rescreening</td>
</tr>
<tr>
<td>M2</td>
<td>Blot haemorrhage or hard exudates within 1 disc diameter of fovea</td>
<td>Refer</td>
</tr>
</tbody>
</table>

BDR – background diabetic retinopathy  
Hemifield – field of image divided by an imaginary line running across the disc and fovea

When grading, the graders first assess the quality of an image on the basis of the clarity of the nerve fibre layer. Images considered of good enough quality are then inspected systematically, starting with the optic disc, then the macula and then all other areas. Using the red free filter is mandatory as it is essential to highlight subtle features such as microaneurysms and IRMA. Other tools such as the zoom and contrast enhancement are used to improve visualisation. A ruler is used to measure the size of blot haemorrhages and to measure the distance of exudates and blot haemorrhages from the fovea (in disc diameters) in order to set the maculopathy grade. Table 1 shows the different grades and their outcomes.

**Conclusion**

Screening has proved to be a vital tool in the fight against DR-related visual loss. An important measure of the successful implementation of screening is the reduced incidence of blindness due to sight-threatening diabetic retinopathy.

**References**


**Figure 3a. New vessels at the disc.** There are new vessels at the optic disc, indicating high risk proliferative retinopathy. Note that there are few other signs of retinopathy, and you might miss the disc vessels if you are not looking for them

**Figure 3b. New vessels at the disc (red-free).** The red-free version of this photo shows the new vessels at the optic disc more clearly. Altering the images, e.g. by using red-free, is a valuable tool for detecting retinopathy
Diabetes is a complex disease requiring the involvement of many health professionals. As a result, people with diabetes are faced with multiple appointments and multiple health messages to understand and make sense of. For example, blood sugar levels (and what is ideal), foot health (and warning signs), kidney checks and eye examinations.

As eye care practitioners, we are faced with the challenge of trying to talk to patients – who are often without symptoms – about their vision in relation to their diabetes. We must encourage and support them to return for eye examinations and treatment (see page 68).

Whenever diabetes patients come into our eye clinics, we can also support their overall health and diabetes treatment by offering suitable information, education and support. This is important as good diabetes control helps to slow down the progression of diabetic eye disease.

Here are a few practical things we can do.

- Send regular reminders to other health professionals in the hospital or community to advise patients with diabetes about the importance of annual eye examinations and where to go.
- Discuss the variety of diabetes checks and clinics the patient attends and how often. Encourage patients to keep their appointments and stay in contact with colleagues in other departments, so you can give patients all the information they need. This will help them to obtain and keep appointments.
- Educate patients about how to stay healthy and manage their diabetes (see panel below). This slows down the progression of diabetic eye disease. Even if patients have heard this elsewhere, change takes time, and the education (and encouragement) needs to be ongoing.
- Educate patients about their individual situation. Use their own retinal images to show them any changes (without blaming them!) or use the poster on pages 70–71. The far right-hand column in the poster contains suggestions for how to talk to patients about what is going on, and what is likely to happen next.

Making lifestyle changes is difficult. We must empower patients with information and support, so they can take an active role in their own health — including coming for follow-up appointments and treatment. We can also lead by example by ensuring that we follow the advice below ourselves.

With thanks to Tunde Peto and Peter Blows

Information for patients: living with diabetes and protecting your eyes

### Medication

Take your medication regularly. Set an alarm (e.g., using a phone) as a reminder, or ask a family member to help remind you.

Eat something just before taking your medication as this will reduce the likelihood of having an upset stomach.

### Eating and drinking

In order to keep blood glucose levels as stable as possible, pay attention to foods that affect your blood glucose — e.g., fruit, fruit juice, potatoes, rice, and so on.

- Eat three regular meals a day. Missing a meal, or doing more exercise than usual, can result in hypoglycaemic episodes (low blood glucose levels). This is characterised by shaking, pounding heart, nervousness, sweating, tingling, and hunger. If left untreated, it can lead to unconsciousness.
- Plan meals that look like the plate in Figure 1: ½ a plate should contain vegetables (i.e., what you can hold in two hands), ¼ plate should contain starchy foods (i.e., the size of your fist) and ¼ plate should hold protein (i.e., the size of the palm of your hand).
- Some starchy foods/carbohydrates break down more slowly than others, and are therefore better for keeping your blood sugar stable. Where available, choose wholegrain or brown bread rather than white, whole potatoes rather than mashed, yams/sweet potatoes rather than ordinary potatoes.
- Eat a maximum of three portions of fruit a day — each portion at a different time of the day.
- Don’t drink more than one glass of fruit juice per day as they are full of sugars.
- Avoid sugary drinks, e.g., cola — drink plenty of water instead.
- Avoid alcohol as it makes hypoglycaemia more likely to occur. Alcohol can raise blood pressure and lead to weight gain.
- Sweets, biscuits and cakes can be eaten once in a while as a treat, i.e., once a week.
- Avoid eating visible fat (cut it off the meat before you eat it)
- Avoid fried foods — steamed or baked is better.

*Figure 1. A healthy plate*

### Exercise

- Exercise helps to lower blood pressure, glucose and cholesterol levels, improves energy levels and general well being, and promotes weight loss. Exercising for 30–50 minutes at least 4–5 times a week is best, but you can start with as little as 20 minutes 3 times a week and build it up from there. Ask for advice from a doctor.
The new Diabetic Retinopathy Network (DR-NET) links 15 hospitals in 10 low- and middle-income countries to share experiences and support each other to identify and treat more patients with diabetic retinopathy. The need is great: in the catchment areas served by the 15 institutions, nearly 400,000 people are estimated to have diabetic retinopathy (DR), but fewer than 10,000 are currently identified and receiving the appropriate treatment. By identifying patients with diabetic retinopathy early, more people will have their sight saved and the number of people going blind unnecessarily across the Commonwealth will be reduced.

The DR-NET was established in 2014 with a grant from the Queen Elizabeth Diamond Jubilee Trust to the Commonwealth Eye Health Consortium, which is based at the International Centre for Eye Health (ICEH) and works with multiple partners internationally. The project was initiated by the VISION 2020 LINKS Programme, which had been requested by partners to develop DR as a priority area for capacity development and shared learning (http://iceh.lshtm.ac.uk/vision-2020-links-programme/). The DR-NET benefits from established VISION 2020 LINKS partnerships between eye units in the UK and Africa plus some from other continents. LINKS in countries outside the Commonwealth also joined the DR-NET to share learning.

The DR-NET was launched with a workshop in November 2014, attended by more than 70 participants. Representatives from each LINK included an ophthalmologist, a diabetologist, a Ministry of Health (MoH) representative and an ophthalmic nurse or DR screener. This representation promoted coordinated planning and ownership of the project by key healthcare workers and the MoH in each country.

Strengths and weaknesses of current service provisions were discussed and each of the participating LINK teams developed a two-year DR detection and treatment plan for their district or country. The teams focussed their discussions on three key questions of planning: “Where are we now? Where do we want to be? How do we get there?”

Advocacy with the Ministry of Health and non-governmental agencies was identified as a priority in all the action plans, as financial and political support is needed so that projects can be implemented successfully.

In total, the participating LINKS partners serve approximately 3.8 million people with diabetes, of whom an estimated 10% have visually threatening diabetic retinopathy (VTDR) requiring treatment. Currently less than 2.5% of the people suspected of having VTDR are identified and receiving treatment.

During the workshop, a commitment was made by all the LINKS teams to increase treatment of DR by at least one patient per week. Over the course of the five-year project, the teams will treat at least 3,750 more patients. Assuming an average of ten years life expectancy at the time of treatment, it is estimated that the DR-NET will prevent a minimum of 37,500 years of blindness.

A key aspect of the project is the development of an ongoing network between the partners for sharing experiences and supporting each other. A virtual networking platform has been established (https://sites.google.com/site/drnetscomm/) through which each partner is sharing data on the number of patients screened and treated each month, and also tools that can be used for training, data collection etc.

Over the five years of the project, each of the DR-NET LINKS will work with the MoH in their country to develop a framework for DR screening and treatment services. There will be regular training visits between partners to build capacity for DR screening and treatment services. To ensure sustainability the DR-NET is promoting the integration of services into the general health system with a strong focus on training and capacity-building.

Since the workshop, participants have made remarkable progress on the development of national plans for DR services. For example, a national framework for DR services in Botswana has been developed which also includes the use of the Portable Eye Examination Kit (Peek) in outreach screening.

Although the DR-NET is a time-limited five-year project (until 2019) it is envisaged that the emphasis on building capacity (training, equipment, tools and systems) to identify and treat patients with diabetic retinopathy will result in a lasting legacy to reduce blindness from diabetes in low- and middle-income settings of the Commonwealth.

**Peek Vision**

Peek, the Portable Eye Examination Kit, is a set of diagnostic tools that allows eye care workers to use a smartphone to screen eye patients. It makes use of 'cloud'-based systems to enable data sharing, referral and follow-up of patients.

Peek Retina is an adapter placed over the camera of a smartphone that enables retinal imaging. It has been trialled in Kenya as a prototype, showing it to be comparable to a desktop camera for optic nerve imaging. Further studies are underway to validate its use for diabetic retinopathy and malaria retinopathy.

A diabetic retinopathy screening system including Peek Acuity and Peek Retina is currently being built and trialled in Tanzania. The team hopes to make this widely available once it is fully functional and the programme evaluation is complete. Peek apps will be free to download from the Google Play store once ready for release. Peek Retina is anticipated to be complete and ready for shipping in 2016. To keep updated on our research, release dates and news, please sign up to our newsletter at www.peekvision.org

---

© The author/s and Community Eye Health Journal' 2015. This is an Open Access article distributed under the Creative Commons Attribution Non-Commercial License.
Understanding and safely using ophthalmic lasers

Ismael Cordero
Clinical Engineer, Philadelphia, USA.
ismaelcordero@me.com

Ophthalmic lasers allow precise treatment of a range of eye problems with little risk of infection. Many laser procedures are relatively pain free and can be performed on an outpatient basis. The combination of safety, accuracy, and relative low cost make lasers very useful ophthalmic tools.

The word laser is an acronym for ‘Light amplification by stimulated emission of radiation’. Laser light is coherent (the waves are in phase in space and time), monochromatic (just one colour or wavelength), and collimated (light is emitted as a narrow beam in a specific direction). Laser beams are produced by the excitation of atoms to a higher than usual energy state. Laser light (radiation) is emitted as the atoms return to their original energy levels.

The main components of a laser system are the laser console, the foot pedal, and the laser delivery system. Different delivery systems, connected to the console by a fibre optic cable, can be used to transmit the laser energy to the patient’s eye (Figure 1): an endoprobe (a small fibre optic probe that is inserted into the eye), a slit lamp, an operating microscope, or an indirect ophthalmoscope.

Different types of lasers emit specific wavelengths of light and are used to treat specific eye problems. Lasers are commonly named according to the active material used. For instance, an argon laser contains argon gas as its active material, whereas the YAG laser contains a solid material made up of yttrium, aluminium, and garnet.

The effects that lasers have on eye tissues are both a function of the molecular composition of the tissue and of the wavelength and power of the laser light. Lasers essentially destroy tissue in order to have a beneficial effect on the eye.

The argon laser emits blue-green wavelengths, which are absorbed by the cells under the retina and by the red haemoglobin in blood. These blue-green wavelengths can pass through the fluid inside the eye without causing damage. For this reason, the argon laser is used extensively in the treatment of diabetic retinopathy. The argon laser can burn and seal the leaking blood vessels, also known as photocoagulation.

Retinal detachment is another serious eye problem that can be treated using an argon laser. The laser is used to weld the detached retina to the underlying choroid layer of the eye. Some forms of glaucoma may also be treated with argon lasers. For instance, angle-closure glaucoma can be treated by using an argon laser to create a tiny hole in the iris (a capsulotomy), which allows excess fluid inside the eye to drain to reduce pressure.

Macular degeneration is sometimes treated with an argon or krypton laser. In this treatment, the laser is used to destroy abnormal blood vessels so that haemorrhage or scarring will not damage central vision.

The YAG 1064 nm infrared laser generates short-pulsed, high-energy light beams to cut, perforate, or fragment tissue. For patients that develop posterior capsular opacification after receiving cataract surgery, the YAG laser is commonly used to vaporise a portion of the capsule, allowing light to fully reach the retina. A frequency-doubled YAG green laser (wavelength 532 nm) can also be used to create a capsulotomy to treat angle-closure glaucoma, producing similar results to that of an argon laser.

The diode laser has similar applications to both the argon and the YAG laser. The advantage of diode lasers is that they are much smaller and portable, produce less heat, and require much less maintenance than other types of lasers.

Lasers units also include a red pointer or target laser beam, which causes no harm to the tissue, to enable the surgeon to see where the treatment laser shots will land.

Using lasers safely

To ensure safe operation and prevent hazards and unintended exposure to laser beams you must follow protective measures:

- To prevent unwanted exposure to laser energy, always review and observe the safety precautions outlined in the operator manuals before using the device.

‘Lasers essentially destroy tissue in order to have a beneficial effect on the eye’
Urine testing is relatively cheap and easy to do. Urine testing can be used to check for blood in the urine, to check for infection (by detecting the presence of white blood cells or protein) and can show up other systemic problems such as liver problems (by showing abnormal bilirubin levels). Urine testing can also detect ketones in the urine. Ketones are by-products of metabolism which form in the presence of severe high blood glucose. The presence of ketones in the urine therefore indicates that patients’ blood glucose level is likely to be very high and that they may have ketoacidosis, which is a potentially life-threatening complication of diabetes and needs urgent treatment. Early signs of ketoacidosis include passing large amounts of urine, severe thirst, feeling nauseous, tiredness, abdominal pain and shortness of breath. Advanced signs include rapid breathing, rapid heartbeat, vomiting, dizziness, confusion and drowsiness; patients may even lose consciousness. Urgently refer patients with any of the above signs.

Although not as accurate as a blood glucose test, urine testing can be used as a screening tool in patients known to have diabetes. Even in patients with no ketoacidosis, high glucose levels may be an indication that their diabetes is poorly controlled. These patients can be referred for counselling, patient education, and – as soon as possible – for an eye examination to look for signs of diabetic retinopathy. Urine testing can also be used to detect glucose in the urine in undiagnosed patients; they will need to be referred for further tests and perhaps a diagnosis of diabetes. All patients with diabetes should have an eye examination once a year.

Before you start
• Confirm that there is an standing order or request for the test to be conducted.
• Explain to the patient what you are going to do and why.

What you need
• Personal protective equipment: gloves, eyewear (plus apron if available)
• Reagent strips – check the expiration date prior to use
• Reagent strip container with colour chart
• Clean container for collection of urine
• Optional: bedpan or bottle for patient unable to access a bathroom

Note: Reagent strips should be stored according to the manufacturer’s instructions.

Procedure
• Give the patient the clean container and explain to them how to obtain a clean specimen of urine. Remind them to wash their hands both before and after using the toilet.
• Depending on the patient, they can be asked to wipe around their genital area with a wet-wipe prior to sampling in order to ensure there are no external contaminants.
• If possible, ask the patient to urinate a little first before then urinating into the container. A mid-stream specimen most accurately represents the urine in the bladder.
• Let them know how much you need, i.e. fill the container three-quarters full, then place the lid on the top.
• If the patient is unable to perform this themselves, they will need assistance.
• Wash your hands and put gloves on prior to taking the container from the patient.
• Remove the lid and dip the reagent strip into the urine, completely immersing the strip in the urine (Figure 1). Remove immediately and tap on the side of the urine container to shake off the last drops.
• Hold the strip at an angle to allow any remaining urine to drain away.
• Wait the required time (as outlined on the reagent strip container) before determining the results by comparison with the colour chart on the side of the reagent strip container (Figure 2). Be careful not to touch anything, whether the side of the reagent strip container or any other surface.
• Dispose of the urine in an appropriate manner.
• Dispose of the contaminated equipment (gloves, reagent strip and urine container, if disposable) as your policy for clinical waste dictates.
• Remove gloves and wash hands.
• Record your readings in the patient’s care notes.
• If readings are abnormal for the patient, pass the information on to someone who is responsible for the patient’s care.
The East Africa Trachoma/NTD Cross-border Partnership

Eastern Africa, which comprises Eritrea, Ethiopia, Kenya, South Sudan, Sudan, Tanzania and Uganda, has the highest burden of trachoma in the world. In sub-Saharan Africa, there are 1,274 districts known to be endemic for trachoma (i.e., the incidence of trachomatous inflammation – follicular (TF) is > 5%). Of these, 769 are found within the seven Eastern African countries, which represents over 60% of the trachoma endemic districts and 50% of the at-risk population in sub-Saharan Africa.

Cross-border movement amongst the pastoralist communities along the long, porous, common borders within Eastern Africa are highly significant in terms of disease transmission and control. It is likely that no single East African country can achieve and sustain elimination unless its neighbours do the same.

As the target date of the year 2020 for the Global Elimination of Blinding Trachoma (GET 2020) approaches, it is evident that we need to coordinate, intensify and align our efforts within each endemic country and across the common borders. We need a common platform to discuss funding, logistics and drug supply chain management issues. Most importantly, we need to share best practices and draw lessons from the challenges facing each individual country programme.

In order to achieve this, a sub-regional consultative meeting involving the seven countries in East Africa was held to deliberate on these issues and decide future directions. This is similar to a cross-border initiative established in West Africa in 2010 to address neglected tropical diseases in five countries. The initiative, called “END in Africa”, is supported by USAID and managed by an NGO called FHI360.

The first Eastern Africa regional meeting took place in July 2015 in Machakos, Kenya with the theme “Strengthening Cross-border Collaborations and Partnerships to achieve Trachoma/NTD Elimination.” The seven countries in the region were represented by two Ministry of Health delegates each: the national NTD coordinator and the national trachoma programme focal person. Nearly all of the relevant NGOs and funding partners in the region were in attendance, and it was decided to form a coalition, known as the East Africa Trachoma/NTD Cross-border Partnership. Overall, participation in both plenary and group discussions was strong and enthusiastic. The future of the partnership, and its impact on trachoma/NTD elimination, shows promise.

The partnership aims to further the global goal of trachoma and NTD elimination by enhancing programme performance and instilling a spirit of urgency and healthy competition among the Eastern African countries. The initiative’s specific objectives can be summarised as follows.

1. Create a regional platform for exchanging experiences among participating countries and their respective partners.
2. Identify programmatic bottlenecks and challenges and recommend practical solutions.
3. Ensure that countries are adhering to World Health Organization (WHO)-recommended strategies and standard operating procedures and guidelines.
4. Assess resource gaps for SAFE implementation (Surgery, Antibiotics, Facial cleanliness and Environmental Improvement) and advocate for resource mobilisation.
5. Design strategies for tackling cross-border challenges.

Several country-specific and general recommendations were outlined at the conclusion of the meeting. The partnership recommended that:

- The International Trachoma Initiative (ITI) acts as the secretariat for the group and that it organises an annual meeting to discuss East African cross-border issues.
- The secretariat set up a communication platform for information sharing between partners.
- ITI propose clear guidance for countries seeking Zithromax® donations for treatment in camps for internally displaced persons and refugees.
- Partners look for opportunities to promote awareness of cross-border trachoma collaborations and conduct activities for advocacy and awareness-raising.
- Each country’s Ministry of Health advocate for government and private funding to support cross-border issues and that they match and leverage partner funding.
- All partners engage with WASH (water, sanitation and hygiene) sector stakeholders in implementing the full SAFE strategy.
- The secretariat work with country NTD point persons to follow up on recommendations.

Eastern African countries should consider regional trachoma elimination plans that allow for joint planning and coordination of antibiotic distribution along the endemic border areas to reduce possible reinfection and accelerate towards elimination goals.

Collaborative programming allows neighbouring countries to identify common strategies for trachoma control in refugees and internally displaced persons. Opportunities for collaborative trachoma control are further enhanced when countries with common borders are supported by the same funding and implementation partners. A follow-up virtual meeting has taken place in early 2016. The next in-person meeting will be held in Arusha, Tanzania.
Test your knowledge and understanding

This page is designed to help you test your own understanding of the concepts covered in this issue, and to reflect on what you have learnt. We hope that you will also discuss the questions with your colleagues and other members of the eye care team, perhaps in a journal club. To complete the activities online – and get instant feedback – please visit www.cehjournal.org

CONTINUING PROFESSIONAL DEVELOPMENT (CPD)

1. Consider diabetes and its link to diabetic retinopathy. Which statement is correct? Select one

a. Diabetes kills fewer people than TB and HIV
b. The risk of developing type 2 diabetes can be reduced by keeping to a healthy weight, taking regular exercise and minimising sugar intake
b. If a patient’s diabetes and blood sugar levels are well controlled, there is no risk of DR
d. If a patient has diabetic retinopathy, they are usually aware of it

2. Consider diabetic retinopathy in individual patients. Which statement is correct? Select one

a. Diabetic retinopathy (DR) affects only people with high blood pressure
b. If a patient’s diabetes and blood sugar levels are well controlled, there is no risk of DR
c. Laser treatment will improve vision in people with DR
d. The risk of blindness from DR can be avoided if patients attend hospital appointments as required and accept treatment

3. Consider diabetic eye disease as a public health problem. Which statement is correct? Select one

a. Blindness from diabetic retinopathy can be prevented by a screening programme
b. Blindness from diabetic retinopathy is mostly linked with patients unable to afford services
c. The risk of blindness from diabetic retinopathy can be reduced through early detection and treatment
d. Blindness from diabetic retinopathy occurs mostly in high-income countries

4. Consider the prevention of diabetic eye disease in your district. Which of the following is essential? Select one

a. Good links with other health workers involved in caring for patients with diabetes (e.g., physicians, diabetes nurses)
b. A community-based survey to determine the number of people with diabetes in your country
c. A national diabetic retinopathy screening programme
d. Enough ophthalmologists to examine every patient with diabetes at least once every year

ANSWERS

Q1. What is the most likely diagnosis?

a. Papilloedema due to a brain tumour
b. Proliferative diabetic retinopathy
c. Hypertensive retinopathy
d. Coat’s disease
e. Non-proliferative diabetic retinopathy

Correct answer: b. Proliferative diabetic retinopathy

Q2. Which of the following clinical signs are present?

a. Vitreous haemorrhage
b. Neovascularisation of the retina
c. Retinal haemorrhages
d. Retinal hard exudates
e. Retinal “cotton wool spots”

Correct answer: d. Retinal hard exudates

Q3. What treatments might be useful in managing this condition?

a. Pattern laser treatment to the macular area
b. Peripheral retinal photocoagulation
c. Investigation of papilloedema
d. Watch and review in 3 months
e. Anti-vascular endothelial growth factor intra-vitreal injections

Correct answer: a, b, c, d, e

ANCHORS OF BRAIN damage (now referred to as 'smooth lesions') and areas of cotton-wool spots and hard exudates in addition to traction retinal detachments and incomplete breaks.

Critical answer: aneurysms can be prevented in most patients by surgical intervention.

Critical answer: diabetic retinopathy is a preventable cause of vision loss and legal blindness.

Critical answer: the test cannot be administered by a non-medical person.

Critical answer: the online “Time to reflect” section.

ANSWERS

Q1. What is the most likely diagnosis?

a. Papilloedema due to a brain tumour
b. Proliferative diabetic retinopathy
c. Hypertensive retinopathy
d. Coat’s disease
e. Non-proliferative diabetic retinopathy

Correct answer: b. Proliferative diabetic retinopathy

Q2. Which of the following clinical signs are present?

a. Vitreous haemorrhage
b. Neovascularisation of the retina
c. Retinal haemorrhages
d. Retinal hard exudates
e. Retinal “cotton wool spots”

Correct answer: d. Retinal hard exudates

Q3. What treatments might be useful in managing this condition?

a. Pattern laser treatment to the macular area
b. Peripheral retinal photocoagulation
c. Investigation of papilloedema
d. Watch and review in 3 months
e. Anti-vascular endothelial growth factor intra-vitreal injections

Correct answer: a, b, c, d, e

REFLECTIVE LEARNING

Visit www.cehjournal.org to complete the online ‘Time to reflect’ section.
Online-only articles
Please visit www.cehjournal.org to read the other articles in this issue:
• Planning DR services: step by step
• Research update: DR in sub-Saharan Africa
• DR services in Fiji: attitudes, barriers and screening practices
• A snapshot of DR in Swaziland
• Developing an effective DR screening service
• Empowering patients with DR
• From the field: educating DR patients on gaining better diabetes control
• Online training for DR screening: iTAT

News and notices
New South Asia edition of the Community Eye Health Journal
We are pleased to announce that the South Asia Edition will soon be available for download to readers in Bangladesh, Bhutan, Maldives, Myanmar, Nepal, Pakistan and India.

IMPORTANT – to ensure you are informed when new issues are published, please send your email address to Shivani Mathur Gaiha at editor@cehjsouthasia.org

The International Edition will continue to be available online at www.cehjournal.org but paper copies will no longer be distributed to readers in these countries.

If your educational or training institution requires paper copies, please call +91 40 4900 6000, write to Akanksha Nigam at the Indian Institute of Public Health, Plot # 1, Rd Number 44, Kavuri Hills, Madhapur, Hyderabad, Telangana 500033, or email editor@cehjsouthasia.org

Teaching institutions
German Jordanian University
Email: vtc@gu.edu.jo

Community Eye Health Institute
www.health.uct.ac.za or email

Diabetes and eye care at the IAPB 10th General Assembly

Durban South Africa
27-30 October 2016

Diabetic macular oedema (which affects around 6.8% of the diabetic population), has started to emerge as a major cause of vision loss, particularly with the increasing prevalence of type 2 diabetes. There is also a shift in management in diabetic retinopathy (DR), with increasing recognition of new intra-ocular therapies. However, there continues to be significant challenges from a public health perspective as many of these therapies are expensive and require significant resources. Furthermore, many patients with DR are unaware of their condition, and many countries do not have well established screening programmes. What can we do?

The IAPB 10th General Assembly will have two courses dedicated to DR:

Course 16: Diabetic Retinopathy (Clinical). Moderator: Tien Wong, Singapore Eye Research Institute

Course 21: Diabetic Retinopathy (Health Systems issues). Moderator: Silvio Mariotti, World Health Organization


Lions Medical Training Centre
Write to the Training Coordinator,
Lions Medical Training Centre,
Lions SightFirst Eye Hospital,
PO Box 66576-00800, Nairobi, Kenya.
Tel: +254 20 418 32 39

Kilimanjaro Centre for Community Ophthalmology International
Visit www.kcco.net or contact Genes Mng’anga at genes@kcco.net

Supported by:

Subscriptions
Contact Akanksha Nigam
editor@cehjsouthasia.org

Subscribe to our mailing list
web@cehjournal.org or visit editor@cehjsouthasia.org


Next issue

The theme of the next issue of the Community Eye Health Journal is on the theme Inequities in eye health: everybody matters